Capreomycin
Also known as: Capastat Sulfate, Capreomycin, Capreomycin sulfate, CMY, CPM, TB‑112
Source Capreomycin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Capreomycin is a cyclic polypeptide antibiotic used as a second‑line injectable therapy for multidrug‑resistant tuberculosis.
Mechanism of Action
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit and interfering with translocation
Routes of Administration
Goals & Uses
- Treatment of pulmonary tuberculosisInfectious DiseaseHigh
- Treatment of multidrug‑resistant tuberculosisInfectious DiseaseHigh
- Treatment of multidrug-resistant tuberculosis (MDR-TB)Infectious DiseaseHigh
- Treatment of extensively drug-resistant tuberculosis (XDR-TB)Infectious DiseaseModerate
Contraindications
- Hypersensitivity to capreomycinAllergyHigh
- Concurrent use of other aminoglycosides or polypeptide antibioticsDrug InteractionHigh
- Severe renal impairment (eGFR <30 mL/min)RenalModerate
- Severe renal impairmentOrganHighKidney function concerns
- Known hypersensitivity to capreomycinAllergyHigh
Adverse Effects
- Leukocytosis or leukopeniaHematologicUncommon
- OtotoxicityAuditory/vestibularCommon
- Electrolyte disturbancesMetabolicCommon
- Injection site pain and indurationLocalCommon
- Neuromuscular blockadeNeuromuscularUncommon
- NephrotoxicityRenalCommon
Drug Interactions
- Aminoglycosides (e.g., streptomycin, amikacin)High
- Neuromuscular blocking agents (e.g., succinylcholine, vecuronium)High
- Nephrotoxic drugs (e.g., NSAIDs, vancomycin, amphotericin B)Moderate
- Loop diuretics (e.g., furosemide, ethacrynic acid)Moderate
- Non‑depolarizing neuromuscular blockersModerate
- Aminoglycosides (e.g., gentamicin)High
Population Constraints
- PregnancyReproductive SafetyRelative
- Patients with pre-existing hearing lossComorbidityRelative
- Neonates and infantsPediatricRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Elderly patientsAgeRelative
Regulatory Status
- European UnionInvestigationalNot marketed; may be accessed via compassionate use programs
- United StatesApprovedApproved: multidrug‑resistant tuberculosisFDA approved as injectable formulation
- United KingdomApprovedApproved: multidrug‑resistant tuberculosisAvailable through specialist TB centers
Approved in the United States and several other jurisdictions for MDR‑TB; limited availability in Europe.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Capreomycin?
Capreomycin is a cyclic polypeptide antibiotic used as a second‑line injectable therapy for multidrug‑resistant tuberculosis.
What is Capreomycin used for?
Capreomycin is educationally associated with: Treatment of pulmonary tuberculosis, Treatment of multidrug‑resistant tuberculosis, Treatment of multidrug-resistant tuberculosis (MDR-TB), Treatment of extensively drug-resistant tuberculosis (XDR-TB). Educational only — not medical advice.
How is Capreomycin administered?
Recorded routes of administration: Intramuscular, Intravenous.
What are the potential side effects of Capreomycin?
Reported adverse effects include: Leukocytosis or leukopenia, Ototoxicity, Electrolyte disturbances, Injection site pain and induration, Neuromuscular blockade, Nephrotoxicity. This list is not exhaustive — consult a qualified clinician.
Who should avoid Capreomycin?
Recorded contraindications: Hypersensitivity to capreomycin, Concurrent use of other aminoglycosides or polypeptide antibiotics, Severe renal impairment (eGFR <30 mL/min), Severe renal impairment, Known hypersensitivity to capreomycin. Consult a qualified clinician before use.